Over the past year, Biogen's stock has experienced a steep decline, with a 1-year change showing a drop of nearly 39.8%. Trading at a P/E ratio of 14, InvestingPro analysis indicates the stock is currently undervalued, with 12 additional ProTips available for subscribers. Investors and analysts are closely monitoring the company's strategic moves to recover from this downturn and reposition itself for future growth. Discover comprehensive insights and detailed valuation metrics in the Pro Research Report, available exclusively to InvestingPro subscribers. Over the past year, Biogen's stock has experienced a steep decline, with a 1-year change showing a drop of nearly 39.8%. Trading at a P/E ratio of 14, InvestingPro analysis indicates the stock is currently undervalued, with 12 additional ProTips available for subscribers. Investors and analysts are closely monitoring the company's strategic moves to recover from this downturn and reposition itself for future growth. Discover comprehensive insights and detailed valuation metrics in the Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Biogen Inc (NASDAQ:BIIB). has been the subject of several significant developments. The company's Alzheimer's treatment, Leqembi, has been forecasted by a Jefferies analyst to generate revenue of $466 million in 2025, below the consensus estimate of $494 million. The analyst further projected a significant decline in Biogen's Ocrevus royalties by 2030 due to potential FDA approval of a biosimilar, leading to a downgrade of the stock from Buy to Hold.
In contrast, Baird increased its price target for Biogen to $300, following a positive reexamination recommendation for lecanemab, another Alzheimer's treatment, by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This development is expected to boost the likelihood of the drug's approval by the European Commission.
In a similar vein, Biogen and Eisai Co., Ltd. (TYO:4523) received a positive CHMP recommendation for lecanemab, which is under review in 17 countries. The drug's approval is based on significant results from Eisai's Phase 3 Clarity AD clinical trial.
On the financial analysis front, Citi initiated coverage on Biogen with a neutral rating and a $190 price target, while TD (TSX:TD) Cowen projects a return to growth for Biogen, driven by the performance of Leqembi and Skyclarys. However, Morgan Stanley (NYSE:MS) downgraded Biogen from Overweight to Equalweight due to a disappointing launch of Leqembi. These are among the recent developments that continue to shape Biogen's trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.